Blog
Women's health

Off Protocol Episode 3: What’s ‘Normal’? The Hidden Burden of Heavy Menstrual Bleeding

Hosted by Lindus Health co-CEO Meri Beckwith, Off Protocol is the podcast that challenges the status quo of clinical trials. Each episode opens the door to honest conversations with experts across the industry — sharing real stories, confronting persistent challenges, and exploring what it takes to run trials that truly work for patients.

This episode focuses on an area of women’s health that has long been overlooked: heavy menstrual bleeding. Despite affecting millions of women worldwide, it remains underdiagnosed, undertreated, and under-researched.

Tune in, as guest host Zara Liew sits down with Dr. Michelle Griffin, women’s health expert advisor for Lindus Health, to explore why this evidence gap persists — and what it will take to close it. The conversation delves into what “normal” really means when it comes to menstruation, the challenges of studying menstrual health, and how thoughtful trial design, digital tools, and patient-centred approaches can finally bring this condition the clinical attention it deserves.

Listen on Spotify

Listen on Apple Podcasts

Listen on YouTube Podcasts

Listen on Amazon Music

This is some text inside of a div block.
This is some text inside of a div block.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.

Continue reading

More from Lindus

Lindus BG Image
11 Mar 2026
Blog

Achieving FDA-Grade Data Quality in Large-Scale Liquid Biopsy Screening Trials

"The data pipeline, from medical record retrieval to structured EDC output, has to be designed for regulatory scrutiny from the start. Retrofitting data quality into an operational model that wasn't built for it creates avoidable risk at exactly the wrong stage of a program."

Lindus BG Image
26 Feb 2026
Blog

Maintaining Complete Long-Term Follow-Up Data in Large-Scale Oncology Screening Trials

Every cancer case in a large screening trial must be fully documented, with complete diagnostic, staging, treatment, and outcome data. Losing even a small number of cases to incomplete follow-up can undermine the statistical power the entire study was designed to achieve. The operational model has to be built around preventing that from the start.

Lindus BG Image
17 Feb 2026
Blog

Scaling Liquid Biopsy Trial Enrollment Through Decentralized and Hybrid Models

"Clinical trials for diagnostics are increasingly time-consuming and expensive, given the large volumes of patients required. Identification and proper enrollment at accredited sites alongside novel methods of reaching patients remotely are promising developments for speeding and focusing efforts."

Lindus BG Image
20 Jan 2026
Blog

Why the FDA's Bayesian Draft Guidance Matters for Clinical Development

Last week, the FDA published draft guidance designed to facilitate the use of Bayesian methodologies in clinical trials of drugs and biologics. It is a welcome step toward faster, more practical clinical development that puts patients first, especially those for whom a clinical trial is often their best hope.